News Updates

The UK's National Institute of Health and Care Excellence has recommended Bristol Myers Squibb's Opdivo, or nivolumab, as a first-line treatment, combined with chemotherapy, to treat rare forms of advanced gastroesophageal cancer such as untreated HER2-negative, advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma if the tumors express PD-L1 with combined positive scores of five or greater. The recommendation was based on clinical results of the CheckMate-649 trial that showed use of Opdivo, combined with CapeOX or FOLFOX chemotherapy, resulted in substantial improvements in progression-free and overall survival. PMLive (UK) (11/25)